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HEMATOPOIESIS AND STEM CELLS
Osteoblastic expansion induced by parathyroid hormone receptor signaling in
murine osteocytes is not sufficient to increase hematopoietic stem cells
Laura M. Calvi,1 Olga Bromberg,1 Yumie Rhee,2 Jonathan M. Weber,1 Julianne N. P. Smith,1 Miles J. Basil,1
Benjamin J. Frisch,1 and Teresita Bellido2,3
1Department of Medicine, Division of Endocrinology, and J. P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY; 2Department
of Anatomy and Cell Biology and 3Department of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN
Microenvironmental expansion of hema-
topoietic stem cells (HSCs) is induced by
treatment with parathyroid hormone (PTH)
or activation of the PTH receptor (PTH1R)
in osteoblastic cells; however, the osteo-
blastic subset mediating this action of
PTH is unknown. Osteocytes are termi-
nally differentiated osteoblasts embed-
ded in mineralized bone matrix but are
connected with the BM. Activation of
PTH1R in osteocytes increases osteoblas-
tic number and bone mass. To establish
whether osteocyte-mediated PTH1R sig-
naling expands HSCs, we studied mice
expressing a constitutively active PTH1R
in osteocytes (TG mice). Osteoblasts, os-
teoclasts, and trabecular bone were in-
creased in TG mice without changes in
BM phenotypic HSCs or HSC function. TG
mice had progressively increased trabec-
ular bone but decreased HSC function. In
severely affected TG mice, phenotypic
HSCs were decreased in the BM but in-
creased in the spleen. TG osteocytes had
no increase in signals associated with
microenvironmental HSC support, and the
spindle-shaped osteoblastic cells that in-
creased with PTH treatment were not pres-
ent in TG bones. These findings demon-
strate that activation of PTH1R signaling
in osteocytes does not expand BM HSCs,
which are instead decreased in TG mice.
Therefore, osteocytes do not mediate the
HSC expansion induced by PTH1R signal-
ing. Further, osteoblastic expansion is
not sufficient to increase HSCs. (Blood.
2012;119(11):2489-2499)
Introduction
To survive throughout the life of an individual, hematopoietic stem
cells (HSCs) must balance self-renewal and differentiation.1 This
essential regulation of stem cells is thought to be determined at
least in part by the environment, or niche, in which these cells
reside.2 Hormonal stimulation by parathyroid hormone (PTH)
results in HSC expansion through the niche,3 but the PTH receptor
(PTH1R) is not expressed in HSCs.4 In the BM microenvironment,
PTH1R is expressed in cells in the osteoblastic lineage, including
Nestin cells, thought to represent mesenchymal stem cells (MSCs),
which recent data suggest are regulatory components of the HSC
niche.5 Because PTH treatment expands the Nestin cell pool and
causes it to more rapidly differentiate into its progeny,5 it is not
known which cells in the mesenchymal/osteoblastic lineage are
responsible for the PTH-dependent signals that result in HSC
expansion. We have demonstrated previously that expression of a
constitutively active PTH receptor (caPTH1R) in immature and
mature osteoblasts was sufficient to expand HSCs.3 Therefore, the
cell population capable of initiating microenvironmental changes
that expand HSCs must comprise osteoblastic cells targeted by the
2.3-kb fragment of the mouse collagen I gene promoter (hereafter
referred to as 2.3Col1 osteoblastic cells) and their progeny, which
includes osteocytic cells.
It was demonstrated recently that PTH stimulates osteocytes, in
which activation of PTH1R signaling down-regulates the expres-
sion of the Wnt antagonist Sclerostin.6 This effect of PTH on
Sclerostin has also been demonstrated in postmenopausal women
treated with PTH,7 suggesting that Sclerostin down-regulation may
be an important mediator of the bone anabolic action of PTH.
Using an in vivo model in which a constitutively active PTH1R is
targeted to osteocytes (dentin matrix protein-1 [DMP1]-caPTH1R
mice, hereafter referred to as TG mice), we demonstrated that
PTH-dependent signals in osteocytes control bone mass and bone
remodeling.8 Osteocytes are former osteoblasts buried into bone
matrix but connected to the endosteum via cytoplasmic processes,9
which sense mechanical stimuli and regulate both osteoblastic and
osteoclastic numbers.10 It was unknown whether osteocytes affect
hematopoiesis and/or HSCs. In the present study, we examined
whether signaling downstream of the PTH1R in osteocytes sup-
ports the expansion of HSCs by analyzing in detail the hematopoi-
etic phenotype of TG mice.
Methods
Generation of TG mice
DMP1-caPTH1R mice were generated using a DNA construct encoding the
H223R mutant of the human PTH1R, as described previously.8
Gene-expression studies
Total RNA was purified from tissues using ULTRASPEC reagent (Biotecx
Laboratories) according to the manufacturer’s instructions. For quantitative
RT-PCR, purified total RNA was reverse-transcribed using the High-
Capacity cDNA Archive Kit (Applied Biosystems). Gene expression was
analyzed in triplicate by quantitative PCR using the Ct method, as
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described previously.11,12 Primer probe sets were designed using the Assay
Design Center of Roche Applied Science and were as follows: for
CXCL-12: forward primer: ctgtgcccttcagattgttg, reverse primer: ctctgcgc-
cccttgttta; Ang-1: forward primer: cggatttctcttcccagaaac, reverse primer:
tccgacttcatattttccacaa; IL-7: forward primer: cgcagaccatgttccatgt, reverse
primer: tctttaatgtggcactcagatgat; IL-6: forward primer gctaccaaactggatataat-
cagga, reverse primer ccaggtagctatggtactccagaa; V-CAM1: forward primer:
tggtgaaatggaatctgaacc, reverse primer: cccagatggtggtttcctt; and ribosomal
protein S2 (used as a housekeeping gene): forward primer: cagaatggtag-
gaaggtcacg, reverse primer: gatcctgctctggaaatcgt.
Histology and immunohistochemistry
Harvested hind limbs were fixed in 10% neutral-buffered formalin for
48 hours, decalcified in 14% EDTA, pH 7.2, for 14 days, and processed as
described previously.8,13 Histological sections (4 m thickness) were
stained with H&E to visualize morphology. For immunohistochemistry, all
slides were deparaffinized, rehydrated with PBS (pH 7.4), treated with
aqueous 3% H2O2 for 20 minutes, and the antigen retrieved in 0.4 mg/mL of
proteinase K (S3004; DAKO) for 10 minutes. Nestin Ab (AB5922;
Millipore) was applied 1:4000 for 60 minutes. The slides were then
incubated in rabbit Ab amplifier (PT03-D; MaxVision) for 15 minutes,
washed in PBS, incubated for 15 minutes in Polymer HRP (PT03-D;
MaxVision). Diaminobenzidine was applied for 10 minutes and then slides
were counterstained with H&E, dehydrated, and mounted with Cytoseal
mounting medium (Richard-Allan Scientific).
Light microscopy
Histology slides were viewed at room temperature with a CKX41 upright
microscope (Olympus). The objectives used were UPlan Fl 20/0.50,
UPlan Fl 40/0.65, and UPlan FLN 60/0.90 (all Olympus). All images
were obtained with a SPOT Insight digital microscope camera and Spot 4.7
software (SPOT Imaging Solutions).
micro-CT analysis
For microcomputed tomography (micro-CT), bones were dissected, cleaned
of soft tissue, and stored in 70% ethanol until being scanned on a model
mCT40 scanner (Scanco Medical), as described previously.8
Peripheral blood cell analysis
Before euthanasia, 20 L of blood obtained by mandibular venous plexus
sampling was run through a CBC-DIFF Veterinary Hematology System
(HESKA) to obtain blood cell counts.
Flow cytometric analysis
Right hind limbs (1 femur and 1 tibia for each individual mouse) and
spleens were harvested from TG mice and their wild-type (WT) littermates
or WT mice treated with PTH. Spleens were collected whole. Whole BM
was isolated either by crushing the tibia and femur with a mortar and pestle
in 10 mL of PBS with 2% FBS and filtering through a 40- mesh or by
cutting both ends of the tibia and femur and flushing the BM with a
25-gauge needle before filtering (WT and TG littermates were always
processed at the same time and using the same method). RBCs were
eliminated from samples by incubating them in RBC lysis buffer (156mM
NH4Cl, 127M EDTA, and 12mM NaHC3) for 5 minutes at room
temperature. Hematopoietic stem and progenitor cells (HSPCs) were
identified by the phenotypic markers LinSca-1c-kit (LSK). 4,6-
diamidino-2-phenylindole (DAPI; Invitrogen) was used to determine the
viability of analyzed cells using control viable and dead cells. LSK cells
were further subdivided into long-term HSCs (LT-HSCs) and short-term
HSCs (ST-HSCs)/multipotent progenitors using the SLAM receptors CD48
Figure 1. Targeted activation of PTH1R in osteocytes increases osteoblastic cells and trabecular bone. (A) Schematic representation of the transgene construct.
(B) Expression of the transgene in tibia and lumbar spine of mice at 3.5 weeks of age. (C-D) H&E staining of longitudinal sections of representative distal femora from
3.5-week-old WT (C,E) and TG (D,F) littermate mice. Bars indicate 0.2 mm (C-D) and 0.05 mm (E-F). *P  .001. (C) Representative longitudinal and cross-sectional micro-CT
images of distal femora from 4-week-old WT and TG littermate mice. Table insert includes quantification of micro-CT parameters (mean  SD) from 3 female and 1 male mice
in each group, age 3.5 weeks. *P  .05
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and CD150 and Flt-3 expression. Stained samples were analyzed on an LSR
II flow cytometer (BD Biosciences) and results were quantified using
FlowJo Version 8.8.6 software (TreeStar). All Abs used are listed in
supplemental Table 1 (available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article).
Competitive repopulation assay
Whole BM from TG and WT sex-matched littermates was obtained
simultaneously with the phenotypic data presented for the same cohort of
mice, using the identical method (flushing or crushing 1 femur and 1 tibia)
for WT and TG donor mice. Care was always taken to use littermate WT
and TG in the same transplantation cohorts. BM cells from the donor
animals were combined with competitor CD45.1 cells at a ratio of 1:2 and
750 000 total cells were transplanted into CD45.1 recipient mice by
tail-vein injection. Before transplantation, the recipient mice received a
split dose of radiation of 500 rads each separated by 24 hours using the
Gamma Cell 40 Irradiator (Best Tetatronic). The second dose of radiation
was given 2 hours before the transplantation. After transplantation, the
peripheral blood of recipient mice was sampled by mandibular bleeds at the
times indicated to monitor engraftment. Blood was separated in a 2%
solution of 5  105 molecular-weight dextran to precipitate the RBCs. The
resulting supernatant containing WBCls was analyzed by flow cytometric
analysis with the Abs listed in supplemental Table 1. 4,6-diamidino-2-
phenylindole (Invitrogen) was used to determine the viability of the collected
cells. Cells expressing CD45.2 came from the original donor group.
Mice
All experiments on mice were approved by the Institutional Animal Care
and Use Committee of the University of Rochester School of Medicine and
the Indiana University School of Medicine.
PTH injections
Rat PTH (1-34) was purchased from Bachem and resuspended in water to
400 g/mL. This solution was diluted 1:100 in sterile 0.9% NaCl solution
and administered intraperitoneally to 8- to 10-week-old C57/BL6 male
mice at 40 g/kg 3 times daily for 10 days. Mice were killed 15 hours after
the last injection. The left hind limb was harvested for histology.
Statistical analysis
For quantitative assays, treatment groups were reported as means  SEM.
For analysis, t tests or ANOVA with Bonferroni posttest were performed
Figure 2. Activation of PTH signaling in osteocytes does not change BM cellularity, phenotypic HSCs, spleen weight, or extramedullary hematopoiesis.
(A-C) Representative flow cytometric dot plot illustrating gating scheme for subsets of LSK cells from the BM from 3.5- to 4-week-old WT or TG male littermate mice. Parent
population is obtained from the FSC and SSC population. The lineage-negative, DAPI-negative population (A) was further analyzed for Sca-1 and c-kit expression (B).The LSK
cell subset was further analyzed for the expression of the SLAM receptors CD150 and CD48 (representative contour plot in panel C) and for Flt-3 (not shown). (D) Total BMMCs
obtained from crushing 1 femur and 1 tibia from each mouse are depicted. LSK cells (E) and subsets for MPPs/ST-LSK (Flt3CD48CD150, F) and LT-LSK
(Flt3CD48CD150, G) are represented as frequency of total. (H) Spleen weights in 4-week-old WT or TG male littermates. (I-K) Spleen LSK cells (I), ST-HSCs (J), and
LT-HSCs (K). The analysis was performed in 2 separate experiments for the BM (WT, n 	 7; TG, n 	 9), 4 separate experiments for the spleen (WT, n 	 17; TG, n 	 18; spleen
weights were obtained in 2 of 4 experiments). Each dot represents an individual mouse; each separate experiment is indicated by a different color; bar indicates the mean and
SEM. None of the results demonstrated a statistically significant difference.
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using Prism Version 4.01 software for Windows (GraphPad). P  .05 was
considered significant.
Results
Targeted expression of a constitutively active PTH1R in
osteocytes increases trabecular bone and osteoblastic cells
To establish whether activation of PTH signaling in osteocytes
expands HSCs, we studied TG mice in which a constitutively
active PTH1R is targeted to osteocytes by the 8-kb fragment of
the DMP1 gene promoter (Figure 1A). Strong expression of the
transgene in both long bones and vertebrae was confirmed in TG
mice as early as 3.5 weeks of age (Figure 1B). At this time point,
TG mice had a large increase in mineralized trabecular bone that
could be seen easily both in histological sections of the long
bones (Figure 1C-F) and by micro-CT analysis (Figure 1G). The
net increase in bone in the TG mice is because of increased bone
formation and osteoblastic cell numbers, not because of defec-
tive osteoclastogenesis or bone resorption, as shown previ-
ously.8 We chose this early time point for initial hematopoietic
analysis of TG mice.
In vivo activation of PTH1R signaling in osteocytes does not
increase BM phenotypic HSCs, spleen weight, or
extramedullary hematopoiesis
The hematopoietic phenotype was studied in 3.5-week-old male
and female mice. In TG mice, there were no changes in peripheral
blood counts (supplemental Figure 1), BM cellularity (Figure 2D),
or splenomegaly (Figure 2H) compared with WT, sex-matched
littermates.
To assess whether activation of osteocytes was sufficient to
expand the immature hematopoietic compartment, flow cytometric
analysis using markers that prospectively identify HSPCs was
performed (Figure 2A-C). BM mononuclear cells (BMMCs) from
crushed WT and TG hind limbs demonstrated similar cellularity
(Figure 2D), and in this cell population, there was no increase in
HSC-enriched LSK cells from TG compared with WT BM (Figure 2E).
HSPC subsets can be discriminated with flow cytometry by
their differential expression of the SLAM receptors CD150 and
CD48 (Figure 2C),14,15 as well as by Flt3 expression.16 Flow
cytometric analysis for HSPC subsets did not identify any differ-
ences in Flt3CD150CD48 phenotypic ST-HSCs (pST-HSCs;
Figure 2F) or Flt3CD48CD150 phenotypic LT-HSCs (pLT-
HSCs; Figure 2G) between BMMCs from WT and TG mice. Even
though spleen weight was not increased in TG mice (Figure 2H), to
Figure 3. Activation of PTH signaling in osteocytes does not change BM HSC function. (A) Schematic representation of the competitive reconstitution experiments.
Donor BMMCs were collected by crushing the hind limbs (1 femur and 1 tibia per each donor mouse) from CD45.2 WT or TG mice, mixed with CD45.1 competitor cells at a ratio
of 1:2, and transplanted into 4-5 irradiated CD45.1 recipient mice to quantify engraftment potential from individual donors. (B) Representative flow cytometric dot plot of total
cells from peripheral blood of donor illustrates how engraftment was quantified. Donor cells are in the right lower quadrant (CD45.2/CD45.1). Individual recipients are
represented as dots (to see this information segregated by donor, see supplemental Figure 2). (C) Results of the competitive repopulation assay. The percentage of
CD45.2/CD45.1–expressing total cells, myeloid cells (CD11b), T cells (CD3
), and B cells (B220) in the blood of recipient mice was analyzed at 4, 8, 12, and 16 weeks
after transplantation as indicated. Each dot represents an individual recipient mouse. Bars indicate the mean and SEM.
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exclude even subtle extramedullary hematopoiesis, we tested total
spleen cells for the presence of phenotypic HSPCs and found no
difference in WT compared with TG mice (Figure 2I-K). These
data demonstrate that neither osteocytic cell activation nor the
osteoblastic cell expansion caused by such activation is sufficient
to expand phenotypic HSPCs.
In vivo activation of PTH1R signaling in osteocytes does not
increase BM HSC function
The lack of an increase in phenotypic HSPCs does not exclude a
change in HSC function, as determined by the ability of HSCs to
reconstitute the hematopoietic system. To determine whether
activation of PTH receptor signaling in osteocytes could expand
functional HSCs, we performed competitive repopulation assays
using BMMCs obtained by crushing one hind limb (1 whole femur
and 1 whole tibia) from WT or TG mice (Figure 3). The competitive
repopulation assay showed that there was no increase in BM HSC
function in TG compared with WT mice in either the short or the
long term (Figure 3C). Analysis of recipients from individual
donors was also performed and, again, no difference was noted
between WT and TG mice (supplemental Figure 2). Therefore,
activation of PTH signaling in osteocytes and subsequent osteoblas-
tic expansion were not sufficient to increase HSC function.
Rapid progression of bone phenotype in mice with activation
of PTH1R signaling in osteocytes decreases BM support for
HSCs
Skeletal changes continue in TG mice as they age, with a
progressive increase in osteoblastic cells and trabecular bone.8
Therefore, the hematopoietic phenotype of TG mice was also
analyzed at later time points. At 4-5 weeks of age, despite severe
increases in trabecular bone in the TG mice, hematopoietic cells
were clearly visualized within the trabeculae in both long bones
(Figure 4A).
When BM and spleen LSK cells were evaluated for phenotypic
HSPCs, we noted decreased LSK cells per limb in TG mice (Figure
4B) and increased LSK cells in the spleens of TG mice (Figure 4C),
suggesting decreased BM microenvironmental support of HSCs in
TG mice. However, we noted a significant change in variance in the
latter measurement (P  .0001 by F test comparing variance of
WT with TG spleen LSK cells), leading us to hypothesize that the
rapid skeletal changes affecting the BM result in a complex
hematopoietic phenotype. Therefore, WT and TG mice were
strictly compared only with sex-matched littermate controls.
Whereas spleen LSK cells were consistent in WT mice (Figure
4D), some litters of TG mice showed no change in spleen LSK cell
frequency (mildly affected TG [TG-A]; Figure 4D). In contrast,
severely affected TG (TG-B) had increased LSK cells in the spleen
(Figure 4D). TG-A mice had no extramedullary hematopoiesis
(Figure 4D), no changes in BM cellularity (data not shown), and no
changes in LSK cell numbers per hind limb or frequency in the BM
(Figure 5A-D). When BMMCs from these WT and TG-A mice
were used as donors for competitive repopulation assays, TG
HSPCs had a significant decrease in both short- and long-term
reconstitution (Figure 5E), suggesting that the changes induced in
the BM by osteocytic activation resulted in decreased BM microen-
vironmental support of LT-HSCs.
In TG-B mice, decreased HSC support by the activated
osteocytes was demonstrated by displacement of LSK cells to the
Figure 4. Mild versus severe hematopoietic phenotype in subsets of TG mice. (A-B) H&E staining of longitudinal sections of representative distal femora (A) from
4-week-old WT and TG littermates. Bars indicate 0.2 mm (low power) and 0.1 mm (high power). Quantification of LSK cells per limb (obtained by flushing 1 femur and 1 tibia per
individual mouse limb, B) and frequency of spleen LSK cells (C). Spleen LSK-cell frequencies are also depicted by litter (D), demonstrating a mild (TG-A) and severe (TG-B)
phenotype. Bars indicate mean and SEM. *P  .05; **P  .01.
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spleen (Figure 4D), decreased BM cellularity (Figure 6A), and
decreased LSK cell number per limb (Figure 6B). Interestingly, in
this group, there was increased LSK cell frequency in the BM
(Figure 6C). Because the proportion of donor cells for the
competitive transplantation assay are numerically based (Figure
3A), the increased LSK cell frequency in the BM would predict
increased reconstitution from TG-B mice resulting from a concen-
tration artifact. Indeed, there was increased donor cell engraftment
in recipients receiving BMMCs from TG mice compared with WT
from this group (Figure 6D). These results highlight the importance
of measuring both the frequency and number per limb of pLT-HSCs
in evaluating the BM and competitive repopulation assay results,
particularly when LSK cell frequency and numbers are discordant
and BM cellularity varies between experimental groups, as de-
scribed previously by others.17
Neutropenia and extramedullary hematopoiesis in 8-week-old
mice with activation of the PTH1R in osteocytes
We next tested WT and TG mice at 8 weeks of age (Figure 7), when
the skeletal phenotype is near maximal, as demonstrated by
changes in histology and bone mineral density.8 Histological
analysis highlighted the dramatic increase in trabecular bone in
both long bones (Figure 7A) and vertebrae (Figure 7B) of TG
compared with WT mice. Despite the trabecular bone increase,
hematopoietic cells could be detected within the BM cavities of TG
mice (Figure 7A-B).
In spleens from TG mice, there was evidence of extramedullary
hematopoiesis, with increased spleen LSK cells (Figure 7C-D),
pST-HSCs (Figure 7E), and pLT-HSCs (Figure 7F) that are
otherwise undetectable in the spleens of mice of this age.
Blood analysis demonstrated normal RBC counts, hematocrit,
and platelets (supplemental Figure 3) in TG mice, whereas WBC
counts were significantly decreased (Figure 7G). This difference
was confirmed with WBC differential counts in TG compared with
WT mice at 8 weeks of age (Figure 7H-J), suggesting defective
hematopoiesis.
Lack of osteocytic pro-HSC signals and absence of
spindle-shaped cells in mice with activation of the PTH1R in
osteocytes
Activation of osteoblastic cells in response to PTH increases
several osteoblastic signals, including CXCL-12 (also known as
SDF-1) and IL-6.3 In addition, other signals have been implicated
in HSC regulation by the niche, including angiopoietin 1 (Ang-1),18
IL-7, and VCAM-1, which were also recently found to be
preferentially expressed in Nestin cells.5 Quantitative RT-PCR
analysis comparing gene expression in bones from TG and WT
mice demonstrated no significant changes in the expression of
these pro-HSC signals (Figure 8A). Therefore, activation of the
PTH1R in osteocytes, while sufficient to expand the osteoblastic
population, did not increase osteocytic signals that have been
reported to mediate microenvironmental expansion of HSCs.
We and others have demonstrated the expansion of an imma-
ture, spindle-shaped stromal population of osteoblastic cells within
the BM cavity in response to activation of PTH signaling in
2.3Col1 osteoblastic cells.13 This population of cells is of particular
Figure 5. TG-A mice have decreased LT-HSC activity. Quantification of BM LSK cells per hind limb (1 femur and 1 tibia). Cells were obtained by both flushing and crushing,
the same method used for TG and WT in the same cohort (A). (B-D) LSK cell frequency (B), BM pST-HSCs (C), and pLT-HSCs (D) in TG-A mice and their WT littermates from
group A. (E) Donor BM from TG-A mice and their WT littermates was collected by flushing, mixed with competitor BM, and transplanted into 10 recipients per group. The
percentage of CD45.2/CD45.1-expressing myeloid cells (CD11b), T cells (CD3
), and B cells (B220) in the blood of recipient mice was analyzed at 4, 8, 12, and
16 weeks after transplantation as indicated. Each dot represents an individual recipient mouse. Bar indicates the mean and SEM. *P  .05.
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interest because it has been suggested recently that PTH treatment
expands Nestin MSCs, which are highly supportive of HSCs in
the BM.5 Immature, spindle-shaped stromal cells, found in close
contact with hematopoietic cells, are greatly expanded during
intermittent PTH treatment, as demonstrated by representative
sections from femora and tibiae (Figure 8B). Cells with these
morphological features were not observed in the TG mice (Figure
8B-D). Immunohistochemistry for Nestin positively identified a
population of rare spindle-shaped cells that were found in associa-
tion with the endosteum and at central locations in the BM (Figure
8C-D), as reported previously,5 whereas osteocytes were Nestin.
Interestingly, a low level of Nestin positivity was detected in
cuboidal osteoblasts lining the trabeculae, perhaps representing an
immature osteoblastic population. In vivo PTH treatment expanded
the Nestin population, although this represented only a subset of
the spindle-shaped cells that were identified morphologically in
both low- and high-power images (Figure 8B-D). However,
Nestin spindle-shaped cells were not expanded in TG mice
(Figure 8C-D).
Discussion
In the present study, we report that in vivo activation of PTH
receptor signaling in osteocytes does not increase HSPC number or
function, despite increases in the osteoblastic cell pool. In fact, in
TG mice, there was a progressive loss of BM support for HSCs. In
contrast, mice with constitutive activation of the PTH1R in
immature and maturing osteoblasts (Col1-caPTH1R) had increased
osteoblastic cells with a corresponding expansion of phenotypic
and functional HSPCs.3 Because PTH binds and activates its
receptor on all cells within the osteoblastic lineage, but not HSCs,
these data shed light on the osteoblastic BM population responsible
for mediating the action of PTH in the BM, establish for the first
time that osteocytic activation of the PTH1R is not sufficient to
augment BM HSCs, and exclude osteocytes as the osteoblastic
population required to initiate PTH-dependent HSC expansion
(summarized schematically in supplemental Figure 4).
Abundant genetic data demonstrate the critical role of osteo-
cytes in bone anabolism. In the setting of activation of osteocytes
by PTH signaling, a robust expansion of the osteoblastic population
has been observed,8 leading to the hypothesis that osteocyte-
dependent osteoblastic expansion may also increase BM HSCs.
Instead, the results of the present study separate PTH-dependent
osteoblastic expansion and its anabolic effect from its ability to
expand HSCs. This disassociation has also been demonstrated in
strontium ranelate treatment.19 Interestingly, recent data in human
osteoblastic cells have suggested that stimulation of Wnt signaling
mediates the osteogenic effects of strontium through decreased
Sclerostin levels,20 which is strongly diminished in TG mice.8
Therefore, these results suggest that potential Sclerostin-targeted
therapies21,22 would not achieve HSC expansion despite their
osteogenic actions.
Interpretation of the present data relies heavily on specific
osteocytic expression of the transgene. The fragment of the DMP1
gene promoter used in TG mice has been demonstrated to direct
Figure 6. TG-B mice have decreased BM LSK cells and increased splenic LSK cells at 4-5 weeks of age. Total BMMCs per limb (A), LSK cells per limb (B), and BM
LSK-cell frequency (C) were quantified from 4- to 5-week-old TG-B and WT male and female littermate mice (n 	 11 TG-B mice and sex-matched littermate controls; each dot
indicates an individual donor; 2 separate experiments are indicated with 2 colors). (D) BMMCs flushed from hind limbs of WT or TG mice, as indicated, were mixed in a 2:1 ratio
with CD45.1 competitor BM cells and transplanted into CD45.1 recipients. The percentage of CD45.2/CD45.1-expressing myeloid cells (CD11b), T cells (CD3
), and
B cells (B220) in the peripheral blood of recipient mice was analyzed at the times indicated after transplantation. Each dot represents an individual recipient mouse. Bars
indicates the mean and SEM. *P  .05; **P  .01; ***P  .001.
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transgene expression specifically to newly embedding and embed-
ded osteocytes.8,10,23,24 The mutated human PTH1R used herein,
which was first described in the setting of Jansen metaphyseal
chondrodysplasia,25,26 is the same mutated receptor used to target
activation of PTH signaling in 2.3Col1 osteoblastic cells, which
results in increased trabecular bone13 and expansion of HSCs.3
Therefore, the lack of HSC expansion in TG mice must be
attributed to the differential effects of equal activation of PTH
signaling in the distinct osteoblastic populations targeted by the
unique promoters used.
The characteristics of the population of cells in the osteoblastic
lineage that supports HSC remain controversial. Recent data
strongly suggest that MSCs provide HSC support within the BM
microenvironment.5 However, data have also supported a role for
more mature osteoblastic cells in HSC regulation. Two studies have
suggested that HSC-supporting cells are osteocalcin osteoblasts,
based on immunofluorescence data demonstrating the proximity of
HSCs to these cells.18,27 Several studies have recently isolated cells
of the osteoblastic lineage28-30 and, whereas some results have
suggested that hematopoietic progenitors are preferentially sup-
ported by immature osteoblastic cells,29,31 others found that mul-
tiple fractions within the osteoblastic lineage could support HSCs,
at least in vitro.28,30 Data on the effects of osteoblastic deficiency
induced in a transgenic mouse model expressing herpesvirus
thymidine kinase gene under the control of a 2.3-kb fragment of the
rat collagen-1 type I gene promoter suggest that osteoblastic cells
targeted by this promoter, as well as their osteoblastic and
osteocytic progeny, comprise the pool of osteoblastic cells capable
of HSC regulation and support.32 Ex vivo coculture systems
designed to specifically identify HSC-supportive cell subsets28-31
have not been evaluated for osteocytic signals and, given the mode
and duration of coculture, are not likely to include osteocytic-type
cells. Because, in TG mice, the osteocyte population is greatly
expanded8 and HSC support is decreased, the results of the current
study also suggest that osteocytes are likely not a regulatory
component of the HSC niche.
The lack of HSC expansion in TG mice provides strong evidence
that immature cells in the osteoblastic lineage mediate the PTH-
dependent HSC increase. Surprisingly, the data presented herein also
suggest that osteocyte-specific activation of PTH signaling instead
diminishes microenvironmental support for HSCs in the BM. This
conclusion is supported by competitive repopulation assays demonstrat-
ing decreased function of HSCs from TG mice characterized by
progressive displacement of phenotypic HSPCs to the spleen and
ultimately by defective hematopoiesis resulting in neutropenia.
The mobilization of immature hematopoietic cells toward
extramedullary sites in TG mice is in contrast to findings in
Col1-caPTH1R mice, in which extramedullary hematopoiesis was
not identified despite thorough analysis of spleen, liver, and
thymus.3 Moreover, in another model of osteoblastic activation also
targeting 2.3Col1 osteoblastic cells, in which there is near oblitera-
tion of the BM cavity, extramedullary hematopoiesis was not
detected.33 Migration of LSK cells and pLT-HSC cells to the spleen
was instead observed with selective deletion of Nestin cells,
which was interpreted as evidence for reduced BM microenviron-
mental support of HSCs in that experimental setting.5 Data have
suggested that murine spleen LSK cells retain their reconstitution
capability.5,34 Therefore, lack of support of HSCs by a cellular
population in the BM, rather than crowding of the BM cavity, may
explain the migration of immature hematopoietic cells to the
spleen, particularly at early time points.
Figure 7. Progression of bone phenotype in TG mice results in neutropenia and dramatically increased LSK cells, pST-HSCs, and pLT-HSCs in spleens. (A-B) H&E
staining of longitudinal sections of representative distal femora (A) and lumbar vertebrae (B) from 8-week-old WT and TG littermate mice. Bars indicate 0.2 mm (low power) and
0.1 mm (high power). Quantification of spleen cellularity (C), frequency of spleen LSK cells (D), pST-HSCs (E), and pLT-HSCs (F) from 8-week-old WT and TG littermate mice.
Quantification of blood WBC (G), monocyte (H), granulocyte (I), and lymphocyte (J) counts in male and female WT and TG littermate mice. Each dot represents an individual
mouse. Bar indicates the mean and SEM. *P  .05; **P  .01; ***P  .001.
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In the present study, neutropenia was identified in adult TG
mice. This finding may represent early evidence of progressive
cytopenias as a result of displacement of phenotypic HSC due to a
reduction of supportive niches in the BM. However, the current
data cannot exclude a decrease in support of myelopoiesis and
myeloid precursors alone or in addition to the effects on HSCs
because of the microenvironmental changes initiated by osteocyte
activation.
PTH-dependent expansion of a population of peritrabecular
stromal cells has been described in PTH excess (hyperparathyroid-
ism),35 with pharmacologic PTH treatment, and in 2.3Col1-
caPTH1R mice.13,36,37 Despite robust osteoblastic expansion, this
Figure 8. Lack of osteocytic pro-HSC signals and absence of spindle-shaped cells in mice with activation of the PTH1R in osteocytes. (A) Quantitative RT-PCR
analysis comparing gene expression in bones from TG and WT mice pro-HSC signals: CXCL12, Ang-1, IL-7, IL-6, and VCAM-1. (B) H&E staining of longitudinal sections of
representative femora and tibiae of 4- to 6-week-old WT, PTH-treated WT, and TG mice, as indicated. Black arrows point to the immature spindle-shaped osteoblastic cells.
Magnification is 20. Bars indicate 0.1 mm. (C) Immunohistochemistry using Nestin Abs of femur from 4- to 6-week-old WT, PTH-treated WT, and TG mice, as indicated.
Arrows point to Nestin spindle-shaped immature osteoblasts, blue hematoxylin. Magnification is 40. Bars indicate 0.05 mm. (D) Immunohistochemistry using Nestin Abs of
tibia from 6-week-old WT, PTH-treated WT, and TG mice, as indicated. Arrows point to Nestin spindle-shaped immature osteoblasts, blue hematoxylin. Magnification is 60.
Bars indicate 0.05 mm.
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population was not increased in TG mice in the present study, a
finding consistent with the activation and expansion of mature
osteoblasts and osteocytes in this model. Definition of these spindle
cells remains elusive, although much data suggest that they
represent an immature osteoblastic population.13,35,36 Our immuno-
histochemistry results are consistent with previous data demonstrat-
ing that PTH expands Nestin MSCs, whereas this population was
not detected in TG mice, resulting in reduced microenvironmental
support for HSCs based on loss of a critical niche population in the
BM. Our studies suggest that the peritrabecular cells, where were
expanded after PTH treatment but not in TG mice, includes the
Nestin MSCs identified by Mendez-Ferrer et al.5
The decreased microenvironmental support of HSCs in TG
mice was unexpected, particularly at times when there was no
reduction in BM cellularity. This unanticipated effect of osteocyte
activation is of great clinical interest, because it suggests detrimen-
tal hematopoietic consequences to the use of therapies that increase
osteoblastic cells and bone by modulating osteocytic products.21
Therefore, our data suggest that hematopoietic parameters should
be monitored in patients receiving therapies that inhibit Sclerostin
function.
In summary, this study demonstrates that, despite increased
osteoblastic cells, activation of PTH signaling in osteocytes does
not expand HSCs and instead leads to decreased BM microenviron-
mental support of HSCs. The progressive loss of BM HSC support
in TG mice may be because of a gradual reduction in immature,
peritrabecular cells. These data strongly suggest that osteocytes and
mature osteoblasts do not support HSCs, and point to less-mature
osteoblastic cells as the stimulatory compartment within the endosteal
HSC niche. These results suggest that therapies aimed at modulating
osteocytic products such as Sclerostin with the goal of expanding
osteoblastic cells may negatively affect BM support of HSCs.
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